SPARC and pachyonychia congenita: In phase I and II, stromal SPARC expression (high and low) was significantly associated with OS in the nab-paclitaxel plus gemcitabine group (17.8 vs 8.1 months), indicating that SPARC may serve as a biomarker for PC.